BMRN as reported
BioMarin Pharmaceutical Inc. reported $3.24B of revenue over the trailing twelve months, +9.9% on the year before. 11 reported series are charted on this page, each one as filed.
$3.24B
Revenue, trailing twelve months · to Q1 2026 · +9.9% against the twelve months before
- Net Income
- $269M
Net Income · −49% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $767M
Free Cash Flow · +23% year on year · trailing twelve months to Q1 2026
- Op Margin
- 9.8%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.24B | +9.9% | Q1 2026 |
| Net Income | $269M | −49% | Q1 2026 |
| EPS | $1.37 | −49% | Q1 2026 |
| Gross Margin | 77% | n/a | Q1 2026 |
| Op Margin | 9.8% | n/a | Q1 2026 |
| Net Margin | 8.4% | n/a | Q1 2026 |
| ROE | 7.4% | n/a | Q1 2026 |
| ROA | 5.8% | n/a | Q1 2026 |
| ROIC | 8.0% | n/a | Q1 2026 |
| Free Cash Flow | $767M | +23% | Q1 2026 |
| P/E | 47.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
BioMarin Pharmaceutical Inc. (BMRN) - Revenue & ProfitRevenue & ProfitBioMarin Pharmaceutical Inc. (BMRN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com